Clozapine use was associated with increased odds of haematological malignancies in a dose–response manner
Exposure to other antipsychotic drugs was not associated with increased odds
Over 17 years of follow-up of the base cohort, 26 deaths occurred due to haematological malignancy among patients using clozapine, whereas only three deaths occurred due to agranulocytosis
Patients and caregivers should be informed about warning signs of haematological malignancies, and mental health clinicians should be vigilant for signs and symptoms of haematological malignancy in patients treated with clozapine.